PBI seeks to engage all stakeholders in our mission to apply state-of-the-art immunotherapy for chronic viral infections and related cancers, first to develop safe and effective treatments for human papillomavirus (HPV) infections and related cancers, and then to expand application of our immunotherapy platforms against other chronic virus infection-related human cancers.
Through presentations at a variety of events and venues, and news releases on diverse media, PBI shares its advances with patients and their families, the scientific community and the public to seek input and support so that we may better achieve our shared goal of improving outcomes for patients with safe and cost-effective new medicines.
